...
首页> 外文期刊>Journal of Diabetes Mellitus >Efficacy and Safety of Patient-Led Dosage Adjustments of Insulin Glargine: A Preliminary Report of Basal-Supported Oral Therapy for Japanese Type 2 Diabetes Patients
【24h】

Efficacy and Safety of Patient-Led Dosage Adjustments of Insulin Glargine: A Preliminary Report of Basal-Supported Oral Therapy for Japanese Type 2 Diabetes Patients

机译:患者主导的胰岛素甘精胰岛素剂量调整的有效性和安全性:日本2型糖尿病患者基础支持的口服治疗的初步报告

获取原文
           

摘要

To evaluate the clinical utility for simple patient administered dose adjustment methods of insulin glargine during outpatient visits compared with a physician managed titration, changes in HbA1c and total daily dose of insulin were evaluated in 23 patients by dividing patients into physician-led (PL) group and self-titration (ST) group who were newly administered glargine basal-supported oral therapy (BOT) while continuing oral antidiabetic drugs at the discretion of their attending physician during regular outpatient visits. In the PL group, one month after initiation of glargine, HbA1c followed a declining trend, although this was not significant (P = 0.07), and decreased significantly after two and three months (P
机译:为了评估门诊就诊时与医生管理的滴定剂量相比,简单的患者接受的甘精胰岛素剂量调整方法的临床实用性,通过将患者分为医生领导的(PL)组,评估了23例患者中HbA1c和胰岛素每日总剂量的变化和自行滴定(ST)组,他们在定期门诊就诊时根据主治医师的判断,在接受新的甘精胰岛素基础口服治疗(BOT)的同时继续口服抗糖尿病药物。在PL组中,甘精胰岛素开始后1个月,HbA1c呈下降趋势,尽管这并不显着(P = 0.07),但在两个月和三个月后显着下降(P

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号